Hiring?
Logo

Cannabinoid Biotechnology

location_on

West, USA

Short Summary

Emerald Health Pharmaceuticals; a biotech company entering Phase 2 human studies with patented unique cannabinoid science & technology focused on diseases like multiple sclerosis and Parkinson's disease; 180+ yrs mgt-team experience; $16M raised.

Overview

Target
NZ$15,000,000
Minimum
NZ$7,800
Investment Raised
NZ$4,700,000
Previous Rounds N/A
Stage Other
Investor Role Silent

Highlights

  • Team with decades of pharmaceutical, biotech and cannabinoid expertise
  • Unique cannabinoid-based new medicines; 16 issued int'l patents, 22 pending
  • Positive results from human phase 1 study for lead candidate, EHP-101
  • Raised US$16M through Regulation A+ financing to date
  • In 11 top medical journals showing preclinical efficacy in targeted disease
Please note: Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. This information has not been approved as a financial promotion, and you must carry out your own due diligence.

Ask a question

Got a question about this project?

Sign up to view the full pitch

It's free to discover the next big thing

Already have an account?

Similar Projects

0% raised

Anti Viral Therapeutics

location_on West, USA

Celestial Therapeutics Inc. (C) is developing new drugs for respiratory infections with no current treatment. 1st product will be for lung infections due to Respiratory Syncytial Virus (RSV) & Influenza Virus. Science is based on Stanford research.

NZ$ 1,500,000

Target

NZ$ 31,000

Min per Investor

Global Pro
6% raised

Trillium Eye Care Pre-IPO

location_on South East, USA

Join this international health care group expand clinics in North America. Convertible Note pays 10% interest which converts into Stock pre-IPO. Company is targeting an IPO in the US at 5X Return to Investors.

NZ$ 2,300,000

Target

NZ$ 7,800

Min per Investor

Global Pro
0% raised

Bleep - DreamPort

location_on South East, USA

Bleep’s DreamPort™ provides the smallest & lightest CPAP mask-solution worldwide, without uncomfortable headgear, pain or leaks, thus revolutionizing CPAP for an estimated 50M end-users & an estimated 938M global sleep-disordered breathing patients....

NZ$ 4,700,000

Target

NZ$ 150,000

Min per Investor

load one similar proposal